JTZ-951
Phase 3Small molecule
JTZ-951 is one of 38 small molecule programs targeting Anemia. It is currently in Phase 3.
1
Indications
4
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
272 competitors in Anemia
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Omontys
TakedaPhase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Vermox
WWim Janssens
Phase 3
Ferrous Sulphate
VVifor Pharma
Phase 3
Epoetin
RochePhase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Aranesp
AmgenPreclinical
Epogen
PfizerPhase 3
JTZ-951
AAkros Pharma Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
End-Stage Renal Disease3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JTZ-951. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAkros Pharma Inc.